Parexel adds former Goldman Sachs partner to board; French gov't awards research consortium €1.28M;

> Parexel ($PRXL) named retired Goldman Sachs partner Maykin Ho to its board of directors. Release

> Parisian biotech Txcell--and a consortium including CRO/CMO Provepep--picked up €1.28 million from the French government to undertake its development of the orphan drug Col-Treg, a new candidate for refractory autoimmune uveitis. Release

> Regis Technologies, a Morton Grove, IL-based CMO, has opened a new site for manufacturing highly potent APIs in its home town. Story

> California-based antibody supplier Santa Cruz Biotechnology has received three complaints from the USDA alleging the company has been mistreating several goats used in its research, including one killed via a firearm without euthanasia. More

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.